About the Company
mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MRSN News
Mersana Therapeutics, Inc. (MRSN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
For the last reported quarter, it was expected that Mersana Therapeutics, Inc. Would post a loss of $0.31 per share when it actually produced a loss of $0.35, delivering a surprise of -12.90%.
Mersana Therapeutics, Inc. (MRSN) Q4 2023 Earnings Call Transcript
Good morning, and welcome to the Mersana Therapeutics Fourth Quarter 2023 Conference Call and Webcast. Currently, all participants are in listen-only mode. There will be a question-and-answer ...
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ...
Mersana Therapeutics Inc (MRSN) Reports Fourth Quarter and Full Year 2023 Financial Results
Warning! GuruFocus has detected 7 Warning Signs with MRSN. Mersana Therapeutics Inc (NASDAQ:MRSN) released its 8-K filing on February 28, 2024, providing a business update and announcing its ...
Mersana Therapeutics Inc MRSN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Q4 2023 Mersana Therapeutics Inc Earnings Call
Good morning, and welcome to the Mersana Therapeutics fourth-quarter 2023 conference call and webcast. (Operator Instructions) Please note this call is being recorded. I would now like to turn the ...
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript
Mersana Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to the Mersana ...
Loading the latest forecasts...